Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C‐III - Ghosh Laskar, M.; Eriksson, M.; Rudling, M.; Angelin, B. (Journal of internal medicine, 2017)
Keywords: Acids; apolipoprotein; Apolipoprotein C-III; Apolipoprotein C-III - blood; Apolipoprotein C-III - drug effects; Apolipoproteins; Bile; Bile acids; Binding; Chenodeoxycholic acid; Chenodeoxycholic Acid - pharmacology; Chenodeoxycholic Acid - therapeutic use; Cholecystectomy; Cholesterol; Cholesterol, LDL - blood; Cholesterol, LDL - drug effects; Diabetes mellitus; Fibroblast growth factors; Gallstones; Gallstones - drug therapy; Humans; Hydroxylase; Hydroxymethylglutaryl-CoA reductase; Insulin; Kexin; Kinetics; LDL cholesterol; LDL receptors; Lipid metabolism; lipoprotein(a); Lipoprotein(a) - drug effects; Lipoproteins; Liver; Liver - enzymology; Liver diseases; Low density lipoprotein; Low density lipoprotein receptors; Male; Markers; Metabolism; Patients; PCSK9; Plasma; Proprotein Convertase 9 - blood; Proprotein Convertase 9 - drug effects; Proprotein convertases; Receptors; Receptors, Cytoplasmic and Nuclear - agonists; Receptors, LDL - metabolism; Reduction; Secretion; Serum levels; Subtilisin; Surgery; Triglycerides; PCSK9; apolipoprotein; LDL cholesterol; lipoprotein(a); chenodeoxycholic acid; LDL receptors